Business
Cuprina Holdings Announces Key Regulatory Milestone in Saudi Arabia and Strengthens Global Scientific Advisory Board
SINGAPORE, March 11, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited ( Nasdaq: CUPR...
About this update from Super Copper Corp.
[{"type":"text","content":"Cuprina Holdings Announces Key Regulatory Milestone in Saudi Arabia and Strengthens Global Scientific Advisory Board\nSINGAPORE, March 11, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today  announced several strategic business developments, including a significant regulatory classification in Saudi Arabia and the expansion of its Medical and Scientific Advisory Board. Regulatory Milestone in Saudi Arabia Cuprina’s 49%-owned associate, Cuprina MENA Co. Ltd, has received official product classification from the Saudi Food and Drug Authority (SFDA) for MEDIFLY, the Company’s medical-grade maggot debridement therapy. The SFDA has classified MEDIFLY as a Medical Device–Drug combination product, with the primary mode of action regulated under the medical device framework. This classification, which allows the Company to finalize the scientific and technical requirements necessary for the commercial distribution of MEDIFLY across Saudi Arabia’s healthcare network, is a critical milestone in Cuprina’s expansion strategy for the Middle East and North Africa (MENA) region. Expansion of Medical and Scientific Advisory Board The Company is also pleased to announce the appointment of Enming Yong to its Medical and Scientific Advisory Board. Dr. Yong is a highly respected Consultant in the Department of Endocrinology at Tan Tock Seng Hospital (TTSH) and serves as an Adjunct Senior Lecturer at the Lee Kong Chian School of Medicine, both located in Singapore.  A graduate of the National University of Singapore (NUS) and a member of the Royal College of Physicians (UK), Dr. Yong brings deep clinical expertise in managing complex metabolic and endocrine conditions, particularly those intersecting with chronic wound care. Under the terms of the strategic advisory agreement signed with Cuprina, Dr. Yong will provide high-level scientific governance, with duties including: Scientific & Development Strategy. Reviewing and advising on scientific protocols, research proposals, and long-term product development strategies.Clinical Oversight. Offering medical perspectives ...